📣 VC round data is live. Check it out!

Absci Valuation Multiples

Discover revenue and EBITDA valuation multiples for Absci and similar public comparables like Theravance, Blue Jet Healthcare, Takara Bio, Chabiotech and more.

Absci Overview

About Absci

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.


Founded

2011

HQ

United States

Employees

157

Website

absci.com

Financials (LTM)

Revenue: $5M
EBITDA: ($115M)

EV

$734M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Absci Financials

Absci reported last 12-month revenue of $5M and negative EBITDA of ($115M).

In the same LTM period, Absci generated $5M in gross profit, ($115M) in EBITDA losses, and had net loss of ($119M).

Revenue (LTM)


Absci P&L

In the most recent fiscal year, Absci reported revenue of $3M and EBITDA of ($103M).

Absci is unprofitable as of last fiscal year, with EBITDA margin of (3684%) and net margin of (4114%).

See analyst estimates for Absci
LTMLast FY202320242025202620272028
Revenue$5M$3M$6M$5M$3M
Gross Profit$5M————
Gross Margin100%————
EBITDA($115M)($103M)($95M)($89M)($103M)
EBITDA Margin(2339%)(3684%)(1669%)(1965%)(3684%)
EBIT Margin(2547%)(4479%)(1647%)(2402%)(4479%)
Net Profit($119M)($115M)($111M)($103M)($115M)
Net Margin(2412%)(4114%)(1934%)(2274%)(4114%)

Financial data powered by Morningstar, Inc.

Absci Stock Performance

Absci has current market cap of $873M, and enterprise value of $734M.

Market Cap Evolution


Absci's stock price is $5.61.

Absci share price increased by 12.8% in the last 30 days, and by 111.9% in the last year.

Absci has an EPS (earnings per share) of $-0.74.

See more trading valuation data for Absci
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$734M$873M14.1%12.8%106.5%111.9%$-0.74

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Absci Valuation Multiples

Absci trades at 148.7x EV/Revenue multiple, and (6.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for Absci

EV / Revenue (LTM)


Absci Financial Valuation Multiples

As of May 5, 2026, Absci has market cap of $873M and EV of $734M.

Absci has a P/E ratio of (7.3x).

LTMLast FY202320242025202620272028
EV/Revenue148.7xn/m128.3x161.9xn/m
EV/EBITDA(6.4x)(7.1x)(7.7x)(8.2x)(7.1x)
EV/EBIT(5.8x)(5.9x)(7.8x)(6.7x)(5.9x)
EV/Gross Profit148.7x————
P/E(7.3x)(7.6x)(7.9x)(8.5x)(7.6x)
EV/FCF(3.3x)(7.8x)(11.2x)(10.1x)(7.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Absci Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Absci Margins & Growth Rates

In the most recent fiscal year, Absci reported EBITDA margin of (3684%) and net margin of (4114%).

See estimated margins and future growth rates for Absci

Absci Margins

Last FY20242025202720282029
EBITDA Margin(3684%)(1965%)(3684%)
EBIT Margin(4479%)(2402%)(4479%)
Net Margin(4114%)(2274%)(4114%)
FCF Margin(3358%)(1606%)(3358%)

Absci Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(21%)(38%)
EBITDA Growth(7%)16%
EBIT Growth16%15%
Net Profit Growth(7%)12%
FCF Growth11%29%

Data powered by FactSet, Inc. and Morningstar, Inc.

Absci Operational KPIs

Absci's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.

Access forward-looking KPIs for Absci
LTMLast FY202320242025202620272028
Rule of 40(2094%)————
Bessemer Rule of X(1727%)————
Revenue per Employee—$0.0M———
Opex per Employee—$0.8M———
G&A Expenses to Revenue716%————
R&D Expenses to Revenue1717%2908%841%1408%2908%
Opex to Revenue—4579%1747%2502%4579%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Theravance5.6x5.4x4.4x—
Blue Jet Healthcare7.7x7.8x18.6x24.5x
Takara Bio2.6x2.6x17.9x—
Chabiotech1.5x—(57.8x)—
MannKind3.0x2.7x20.7x—
ARS Pharmaceuticals8.7x6.7x(4.3x)—
Janux Therapeutics(6.5x)(4.9x)0.4x0.4x
Arbutus Biopharma55.0x76.3x(23.5x)—

This data is available for Pro users. Sign up to see all Absci competitors and their valuation data.

Start Free Trial

Absci Funding History

Before going public, Absci raised $233M in total equity funding, across 6 rounds.


Absci Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Mar-21Undisclosed stageaMoon Fund; ArrowMark Partners; Casdin Capital; D1 Capital Partners; Fidelity; Helicase Venture; Irving Investors; Perceptive Advisors; Redmile Group$125M—AbSci is a synthetic biology company founded in 2011 based in Vancouver, Washington, that unifies biologic drug discovery and development processes. The company's core technology, marketed as Protein Printing, enables the discovery and manufacturing of complex biological molecules such as antibodies and insulin, with the goal of reducing failure rates and accelerating protein biomanufacturing. AbSci provides drug discovery and cell line development services for biopharmaceutical companies, with technology platforms that produce proteins and cell cultures used in drug treatment development. In March 2021, AbSci completed a $125 million crossover financing round co-led by existing investors Casdin Capital and Redmile Group, with participation from new investors Fidelity Management and Research Company LLC, D1 Capital Partners, Perceptive Advisors, aMoon Edge, and Irving Investors, as well as existing investor ArrowMark Partners. The proceeds were designated to support continued growth through research and development activities and strategic investments, with particular focus on integration and training of the Denovium Engine deep learning artificial intelligence platform acquired in January 2021, along with ongoing expansion of core discovery capabilities including non-standard amino acid technologies. In a significant year of capital raising, AbSci had previously secured $65 million in Series E funding in October 2020 led by Casdin Capital, and received an undisclosed investment from Merck & Co's Global Health Innovation Fund in early 2021, bringing total funding to approximately $230 million by March 2021. The company later went public in July 2021 with a $230 million IPO on Nasdaq under the ticker ABSI, marking the largest regional biotech IPO at that time. The round was characterized as crossover financing, a strategy employed by startups preparing for public markets to raise capital from firms traditionally focused on public company investments, particularly common in the life sciences sector.
Oct-20Series EArrowMark Partners; Casdin Capital; Phoenix Venture Partners; Redmile Group$70M——
Jan-20Series DColumbia Ventures Corporation; JSR Life Sciences; KBI Biopharma; Oregon Venture Fund; Phoenix Venture Partners; WRF Capital$10M——
Jan-19Series DJSR; KBI Biopharma$10M—Absci, a Vancouver, Washington-based biotechnology company, develops Protein Printing technology using *E. coli* cell lines for rapid, low-cost biomanufacturing of complex biotherapeutics. The company completed a $10.4 million Series D financing round led by KBI Biopharma and JSR Life Sciences, with participation from existing investors Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Columbia Ventures Corporation. The round, announced around December 2019 but referenced in a July 2019 context, also included $5 million in term debt. Proceeds from the financing supported expansion of Absci's facilities and team to meet commercial demand for its disruptive microbial expression technology, which addresses manufacturing challenges for difficult-to-produce molecules in other protein expression platforms. AbSci reported revenue growth of over 800% in 2019, highlighting aggressive expansion amid rising biopharma industry needs for high-yield production of next-generation biotherapeutics. The financing enabled scaling to improve patient outcomes through innovative therapies. KBI Biopharma, a JSR Group company, partnered with Absci, leveraging its FDA and EMA-approved clinical and commercial microbial manufacturing facilities in Boulder, CO, to translate the technology into new medicines.
May-18Series CAGC; Corporation Ventures; Essential Consultants; Greenbridge Partners; Oregon Venture Fund; Phoenix Venture Partners; Washington Research Foundation$12M—AbSci, a US-based biomanufacturing company founded in 2011, develops synthetic biology platforms for protein expression to accelerate biopharmaceutical discovery, development, and manufacturing. Its SoluPro platform uses genetically engineered E. coli to produce complex molecules like antibodies and insulin, reducing costs and timelines, complemented by the SoluPure purification system. On May 30, 2018, AbSci closed an oversubscribed $12 million Series C funding round led by AGC (Asahi Glass Co.), with participation from Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, Souther Co., Columbia Ventures Corporation, and GreenBridge Partners. The funds supported expanded R&D, scaling production capacity to meet demand from large pharma and biosimilar partners, and commercialization of the SoluPro platform. AGC Biologics President Gustavo Mahler joined AbSci's board as part of the deal. At the time, AbSci employed 24 people and planned significant team growth, building on prior rounds including a $5.1 million Series A in 2016 led by Phoenix Venture Partners.
Feb-16Series AOregon Venture Fund; Phoenix Venture Partners$5M—AbSci secured $5.1 million in Series A financing in April 2016, led by Phoenix Venture Partners with participation from Oregon Venture Fund. The funding aimed to accelerate commercialization of AbSci's SoluPro microbial protein expression platform for biopharmaceutical manufacturing. Phoenix Venture Partners' General Partner Dr. Zach Jonasson joined AbSci's board. AbSci, founded in 2011 and based in Portland, Oregon at the time, specializes in soluble microbial protein expression technology to enhance manufacturing flexibility and efficiency for the biopharmaceutical industry. The company later expanded into AI-powered synthetic biology for drug discovery and protein-based therapies. Subsequent rounds included a Series B by Phoenix Venture Partners in 2017, Series C led by AGC in 2018, Series D of $10.4 million in January 2020, Series E of $65 million in October 2020, and a $125 million crossover in March 2021.

Absci M&A Activity

Absci has acquired 2 companies to date.

Last acquisition by Absci was on June 14th 2021. Absci acquired Totient for $55M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Absci

Totient
Denovium
Description
Totient is a Cambridge-headquartered biotechnology company using AI and machine learning to discover tissue-specific antigens from tertiary lymphoid structures. The Immunogenomics Platform identifies high-affinity antibodies for oncology, autoimmune disorders, and infectious diseases. Founded in 2017, Totient partners with Takeda and generates candidates from patient tumor samples analyzed in its Boston labs.
Denovium is a Boston-based AI company applying machine learning to drug discovery in biopharma. Its platform accelerates hit identification and lead optimization for protein targets, collaborating with pharmaceutical firms on oncology and immunology programs through generative models trained on proprietary datasets.
HQ CountryUnited StatesUnited States
HQ City
—
San Diego, CA
Deal Date14 Jun 202112 Jan 2021
Valuation$55Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Absci acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Absci

When was Absci founded?Absci was founded in 2011.
Where is Absci headquartered?Absci is headquartered in United States.
How many employees does Absci have?As of today, Absci has over 157 employees.
Who is the CEO of Absci?Absci's CEO is Sean McClain.
Is Absci publicly listed?Yes, Absci is a public company listed on Nasdaq.
What is the stock symbol of Absci?Absci trades under ABSI ticker.
When did Absci go public?Absci went public in 2021.
Who are competitors of Absci?Absci main competitors include Theravance, Blue Jet Healthcare, Takara Bio, Chabiotech, MannKind, ARS Pharmaceuticals, Janux Therapeutics, Arbutus Biopharma, Allergy Therapuetics, Alto Neuroscience.
What is the current market cap of Absci?Absci's current market cap is $873M.
What is the current revenue of Absci?Absci's last 12 months revenue is $5M.
What is the current revenue growth of Absci?Absci revenue growth (NTM/LTM) is 245%.
What is the current EV/Revenue multiple of Absci?Current revenue multiple of Absci is 148.7x.
Is Absci profitable?No, Absci is not profitable.
What is the current EBITDA of Absci?Absci has negative EBITDA and is not profitable.
What is Absci's EBITDA margin?Absci's last 12 months EBITDA margin is (2339%).
What is the current EV/EBITDA multiple of Absci?Current EBITDA multiple of Absci is (6.4x).
What is the current FCF of Absci?Absci's last 12 months FCF is ($222M).
What is Absci's FCF margin?Absci's last 12 months FCF margin is (4495%).
What is the current EV/FCF multiple of Absci?Current FCF multiple of Absci is (3.3x).
How many companies Absci has acquired to date?As of May 2026, Absci has acquired 2 companies.
What was the largest acquisition by Absci?$55M acquisition of Totient on 14th June 2021 was the largest M&A Absci has done to date.
What companies Absci acquired?Absci acquired Totient and Denovium.
In how many companies Absci has invested to date?Absci hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Absci

Lists including Absci

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial